Lining Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lining Huang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Xinwei Jiang
Department of Hepatobiliary Surgery, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
3 shared publications Jianwu Wu
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, Suzhou, People’s Republic of China
2 shared publicationsWeiqiao Niu
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, Suzhou, People’s Republic of China
2 shared publicationsXingming Jiang
Second Affiliated Hospital of Harbin Medical University
2 shared publicationsYujia Pan
Center for Scientific Research and Innovation, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, Suzhou, People’s Republic of China
2 shared publications- Yunfu Cui
Department of Pancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, China
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-17
USP9X Promotes Hepatocellular Carcinoma Progression via Stabilization of HSP90AA1
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Ubiquitin-specific proteases (USPs) modulate tumor progression by regulating substrate protein stability. However, the mechanisms of most DUBs in HCC remain poorly understood. This study aimed to investigate the role of USP9X in promoting HCC cell proliferation, survival, migration, and invasion. Methods: Transcriptomic and clinical data of LIHC patients were obtained from TCGA to assess USP9X expression, prognosis, and pathway enrichment. USP9X expression in HCC and adjacent tissues was examined by immunohistochemistry and Western blotting. Functional assays (CCK-8, colony formation, wound-healing, Transwell) were performed following USP9X knockdown or overexpression in Lm3 and Huh7 cells. The USP9X–HSP90AA1 interaction was evaluated by Co-IP and mass spectrometry, and deubiquitination assays elucidated the mechanism. In vitro and in vivo experiments determined the effects of USP9X–HSP90AA1 signaling on HCC growth and metastasis. Results: Bioinformatic analyses revealed that USP9X expression was significantly elevated in LIHC tissues and correlated with poor prognosis. Immunohistochemistry and Western blotting confirmed higher USP9X protein levels in tumor tissues. Knockdown of USP9X inhibited proliferation and migration of Lm3 and Huh7 cells, whereas USP9X overexpression enhanced these phenotypes. Co-IP demonstrated a direct interaction between USP9X and HSP90AA1, and deubiquitination assays showed that USP9X decreased HSP90AA1 ubiquitination and increased its stability. Both in vitro and in vivo data indicated that USP9X promotes HCC progression through stabilization of HSP90AA1. Conclusion: USP9X is a tumor-promoting factor that accelerates HCC progression by stabilizing HSP90AA1, highlighting USP9X as a potential therapeutic target for HCC.
- 1 May 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-17
Open AccessUSP9X Promotes Hepatocellular Carcinoma Progression via Stabilization of HSP90AA1
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Ubiquitin-specific proteases (USPs) modulate tumor progression by regulating substrate protein stability. However, the mechanisms of most DUBs in HCC remain poorly understood. This study aimed to investigate the role of USP9X in promoting HCC cell proliferation, survival, migration, and invasion. Methods: Transcriptomic and clinical data of LIHC patients were obtained from TCGA to assess USP9X expression, prognosis, and pathway enrichment. USP9X expression in HCC and adjacent tissues was examined by immunohistochemistry and Western blotting. Functional assays (CCK-8, colony formation, wound-healing, Transwell) were performed following USP9X knockdown or overexpression in Lm3 and Huh7 cells. The USP9X–HSP90AA1 interaction was evaluated by Co-IP and mass spectrometry, and deubiquitination assays elucidated the mechanism. In vitro and in vivo experiments determined the effects of USP9X–HSP90AA1 signaling on HCC growth and metastasis. Results: Bioinformatic analyses revealed that USP9X expression was significantly elevated in LIHC tissues and correlated with poor prognosis. Immunohistochemistry and Western blotting confirmed higher USP9X protein levels in tumor tissues. Knockdown of USP9X inhibited proliferation and migration of Lm3 and Huh7 cells, whereas USP9X overexpression enhanced these phenotypes. Co-IP demonstrated a direct interaction between USP9X and HSP90AA1, and deubiquitination assays showed that USP9X decreased HSP90AA1 ubiquitination and increased its stability. Both in vitro and in vivo data indicated that USP9X promotes HCC progression through stabilization of HSP90AA1. Conclusion: USP9X is a tumor-promoting factor that accelerates HCC progression by stabilizing HSP90AA1, highlighting USP9X as a potential therapeutic target for HCC.
- Open Access
- 24 November 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (5) , 1873-1888
Prognostic and Immunological Significance of TIPARP in Pancreatic Cancer
Background Pancreatic ductal adenocarcinoma (PAAD) remains one of the most lethal malignancies, with a 5-year survival rate below 10%. TCDD-inducible poly (ADP-ribose) polymerase (TIPARP) is aberrantly expressed in various tumors, but its mechanistic role and clinical significance in pancreatic cancer remain unclear. Methods We analyzed TIPARP expression patterns and prognostic relevance by integrating data from the TCGA-PAAD (n = 178) and GTEx (n = 171) databases. Single-cell RNA sequencing, immune infiltration profiling, and Mendelian randomization analyses were conducted to assess cell-type specificity and causal relationships. The biological functions of TIPARP were validated through in vitro assays, and downstream mechanisms were explored via pathway enrichment analysis. Results TIPARP was significantly upregulated in pancreatic cancer tissues and correlated with worse overall survival (P = 5.9e − 3) and progression-free survival (P = 0.01), serving as an independent prognostic risk factor. A TIPARP-based nomogram exhibited strong predictive performance (C-index = 0.666; 5-year AUC = 0.885). Single-cell transcriptomics identified fibroblasts as the primary TIPARP-expressing cell type. Immune profiling revealed that high TIPARP expression was associated with altered immune cell infiltration and positively correlated with immune checkpoint molecules such as PD-L1 and TIM-3. Mendelian randomization confirmed a causal association between genetically predicted TIPARP expression and increased PAAD risk (OR = 1.511, P = 0.008). Functional assays showed that TIPARP promotes cell proliferation, migration, and invasion, while pathway analysis implicated the PI3K-Akt and ECM-receptor interaction signaling cascades. Conclusion TIPARP is a novel independent prognostic biomarker and potential therapeutic target in pancreatic cancer. It contributes to tumor progression by promoting an immunosuppressive microenvironment and activating pro-tumorigenic signaling. These findings highlight TIPARP as a promising candidate for precision medicine and combination immunotherapy in PAAD.
- 24 November 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (5) , 1873-1888
Open AccessPrognostic and Immunological Significance of TIPARP in Pancreatic Cancer
Background Pancreatic ductal adenocarcinoma (PAAD) remains one of the most lethal malignancies, with a 5-year survival rate below 10%. TCDD-inducible poly (ADP-ribose) polymerase (TIPARP) is aberrantly expressed in various tumors, but its mechanistic role and clinical significance in pancreatic cancer remain unclear. Methods We analyzed TIPARP expression patterns and prognostic relevance by integrating data from the TCGA-PAAD (n = 178) and GTEx (n = 171) databases. Single-cell RNA sequencing, immune infiltration profiling, and Mendelian randomization analyses were conducted to assess cell-type specificity and causal relationships. The biological functions of TIPARP were validated through in vitro assays, and downstream mechanisms were explored via pathway enrichment analysis. Results TIPARP was significantly upregulated in pancreatic cancer tissues and correlated with worse overall survival (P = 5.9e − 3) and progression-free survival (P = 0.01), serving as an independent prognostic risk factor. A TIPARP-based nomogram exhibited strong predictive performance (C-index = 0.666; 5-year AUC = 0.885). Single-cell transcriptomics identified fibroblasts as the primary TIPARP-expressing cell type. Immune profiling revealed that high TIPARP expression was associated with altered immune cell infiltration and positively correlated with immune checkpoint molecules such as PD-L1 and TIM-3. Mendelian randomization confirmed a causal association between genetically predicted TIPARP expression and increased PAAD risk (OR = 1.511, P = 0.008). Functional assays showed that TIPARP promotes cell proliferation, migration, and invasion, while pathway analysis implicated the PI3K-Akt and ECM-receptor interaction signaling cascades. Conclusion TIPARP is a novel independent prognostic biomarker and potential therapeutic target in pancreatic cancer. It contributes to tumor progression by promoting an immunosuppressive microenvironment and activating pro-tumorigenic signaling. These findings highlight TIPARP as a promising candidate for precision medicine and combination immunotherapy in PAAD.
- Open Access
- 4 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (40) , e39983
Case report and literature review: A young man with giant intra-abdominal Ewing sarcoma
Rationale: Extraosseous Ewing sarcoma (EES) is a rare manifestation within the Ewing sarcoma tumor family (ESFT). Its clinical manifestations lack specificity, intestinal obstruction is the main symptom but can also present with abdominal pain, gastrointestinal bleeding, and other discomforts, making it prone to misdiagnosis as intestinal mesenchymal tumor. Patient concerns: A 29-year-old male was admitted to the hospital with intestinal obstruction symptoms and abdominal CT suggesting “left abdominal occupation.” Diagnosis: The patient was initially misdiagnosed as intestinal mesenchymal tumor, and was later definitively diagnosed as abdominal Ewing sarcoma by postoperative pathology and genetic testing. Interventions: Due to the patient’s surgical indication, surgical resection with exploratory laparotomy was performed and then the patient underwent systemic chemotherapy. Outcomes: Intraoperatively, we found a 15-cm tumor originating from the proximal jejunum, with invasion into the peritoneum, duodenum, jejunum, and colon. Finally, the pathological report revealed Ewing sarcoma. Lessons: Giant abdominal Ewing sarcoma with a diameter of 15 cm is rare. Considering postoperative pathology and genetic testing, abdominal Ewing sarcoma was suspected. The patient was successfully treated using surgery.
- 4 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (40) , e39983
Open AccessCase report and literature review: A young man with giant intra-abdominal Ewing sarcoma
Rationale: Extraosseous Ewing sarcoma (EES) is a rare manifestation within the Ewing sarcoma tumor family (ESFT). Its clinical manifestations lack specificity, intestinal obstruction is the main symptom but can also present with abdominal pain, gastrointestinal bleeding, and other discomforts, making it prone to misdiagnosis as intestinal mesenchymal tumor. Patient concerns: A 29-year-old male was admitted to the hospital with intestinal obstruction symptoms and abdominal CT suggesting “left abdominal occupation.” Diagnosis: The patient was initially misdiagnosed as intestinal mesenchymal tumor, and was later definitively diagnosed as abdominal Ewing sarcoma by postoperative pathology and genetic testing. Interventions: Due to the patient’s surgical indication, surgical resection with exploratory laparotomy was performed and then the patient underwent systemic chemotherapy. Outcomes: Intraoperatively, we found a 15-cm tumor originating from the proximal jejunum, with invasion into the peritoneum, duodenum, jejunum, and colon. Finally, the pathological report revealed Ewing sarcoma. Lessons: Giant abdominal Ewing sarcoma with a diameter of 15 cm is rare. Considering postoperative pathology and genetic testing, abdominal Ewing sarcoma was suspected. The patient was successfully treated using surgery.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 10, 1327-1339
Downregulated Acetyl-CoA Acyltransferase 2 Promoted the Progression of Hepatocellular Carcinoma and Participated in the Formation of Immunosuppressive Microenvironment
Background: The aim of this study is to explore the role of acetyl-CoA acyltransferase 2 (ACAA2) in the progression of hepatocellular carcinoma (HCC). Methods: Bulk RNA data and single-cell RNA data were acquired from The Cancer Genome Atlas and Gene Expression Omnibus. Both in vitro and in vivo studies were used to determine the effect of ACAA2 on the progression of HCC, and RNA sequencing analysis was performed to explore the mechanism. Results: We found downregulation of ACAA2 was involved in the malignant progression of HCC. The patient with low ACAA2 level had an immunosuppressive microenvironment in the HCC and predicted to have a poor prognosis. Decreased ACAA2 facilitated HCC proliferation and metastasis by activating the nuclear factor-κB (NFκB) signaling pathway. And increased CXCL1 induced by NFκB signaling pathway might be responsible for low level of ACAA2 related immunosuppressive microenvironment. Furthermore, the expression of ACAA2 was also detected in immune cells. The expression of ACAA2 in CD4+TCF7+T, CD4+FOXP3+T, CD8+GZMK+T, and CD8+KLRD1+T cells was inversely correlated with the composition of CD8+PDCD1+T cells in HCC. This effect might be due to the CCL5-CCRs and HLA-E-KLRCs ligand-receptor networks. Conclusion: In a conclusion, downregulated ACAA2 promoted the progression of hepatocellular carcinoma and might be participated in the formation of immunosuppressive microenvironment. ACAA2 could be served as a favorable indicator for the prognosis of HCC and an ideal biomarker for immunotherapy.
- 1 August 2023
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 10, 1327-1339
Open AccessDownregulated Acetyl-CoA Acyltransferase 2 Promoted the Progression of Hepatocellular Carcinoma and Participated in the Formation of Immunosuppressive Microenvironment
Background: The aim of this study is to explore the role of acetyl-CoA acyltransferase 2 (ACAA2) in the progression of hepatocellular carcinoma (HCC). Methods: Bulk RNA data and single-cell RNA data were acquired from The Cancer Genome Atlas and Gene Expression Omnibus. Both in vitro and in vivo studies were used to determine the effect of ACAA2 on the progression of HCC, and RNA sequencing analysis was performed to explore the mechanism. Results: We found downregulation of ACAA2 was involved in the malignant progression of HCC. The patient with low ACAA2 level had an immunosuppressive microenvironment in the HCC and predicted to have a poor prognosis. Decreased ACAA2 facilitated HCC proliferation and metastasis by activating the nuclear factor-κB (NFκB) signaling pathway. And increased CXCL1 induced by NFκB signaling pathway might be responsible for low level of ACAA2 related immunosuppressive microenvironment. Furthermore, the expression of ACAA2 was also detected in immune cells. The expression of ACAA2 in CD4+TCF7+T, CD4+FOXP3+T, CD8+GZMK+T, and CD8+KLRD1+T cells was inversely correlated with the composition of CD8+PDCD1+T cells in HCC. This effect might be due to the CCL5-CCRs and HLA-E-KLRCs ligand-receptor networks. Conclusion: In a conclusion, downregulated ACAA2 promoted the progression of hepatocellular carcinoma and might be participated in the formation of immunosuppressive microenvironment. ACAA2 could be served as a favorable indicator for the prognosis of HCC and an ideal biomarker for immunotherapy.
- Open Access
- 18 July 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-13
Linc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation
Background: Cholangiocarcinoma (CCA) is a mortal cancer with high mortality, whereas the function and mechanism of occurrence and progression of CCA are still mysterious. Long non-coding RNAs (lncRNAs) could function as important regulators in carcinogenesis and cancer progression. Growing evidences have indicated that the novel lncRNA linc00473 plays an important role in cancer progression and metastasis. However, its function and molecular mechanism in CCA remain unknown. Methods: The linc00473 expression in CCA tissues and cell lines was analyzed using qRT-PCR. Gain- and loss-of-function experiments were conducted to investigate the biological functions of linc00473 both in vitro and in vivo. Insights into the underlying mechanisms of competitive endogenous RNAs (ceRNAs) were determined by bioinformatics analysis, dual-luciferase reporter assays, qRT-PCR arrays, RNA immunoprecipitation (RIP) and rescue experiments. Results: Linc00473 was highly expressed in CCA tissues and cell lines. Linc00473 knockdown inhibited CCA growth and metastasis. Furthermore, linc00473 acted as miR-506 sponge and regulated its target gene DDX5 expression. Rescue assays verified that linc00473 modulated the tumorigenesis of CCA by regulating miR-506. Conclusions: The data indicated that linc00473 played an oncogenic role in CCA growth and metastasis, and could serve as a novel molecular target for treating CCA.
- 18 July 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-13
Open AccessLinc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation
Background: Cholangiocarcinoma (CCA) is a mortal cancer with high mortality, whereas the function and mechanism of occurrence and progression of CCA are still mysterious. Long non-coding RNAs (lncRNAs) could function as important regulators in carcinogenesis and cancer progression. Growing evidences have indicated that the novel lncRNA linc00473 plays an important role in cancer progression and metastasis. However, its function and molecular mechanism in CCA remain unknown. Methods: The linc00473 expression in CCA tissues and cell lines was analyzed using qRT-PCR. Gain- and loss-of-function experiments were conducted to investigate the biological functions of linc00473 both in vitro and in vivo. Insights into the underlying mechanisms of competitive endogenous RNAs (ceRNAs) were determined by bioinformatics analysis, dual-luciferase reporter assays, qRT-PCR arrays, RNA immunoprecipitation (RIP) and rescue experiments. Results: Linc00473 was highly expressed in CCA tissues and cell lines. Linc00473 knockdown inhibited CCA growth and metastasis. Furthermore, linc00473 acted as miR-506 sponge and regulated its target gene DDX5 expression. Rescue assays verified that linc00473 modulated the tumorigenesis of CCA by regulating miR-506. Conclusions: The data indicated that linc00473 played an oncogenic role in CCA growth and metastasis, and could serve as a novel molecular target for treating CCA.
- Open Access
- 24 June 2020
- Published by Springer Nature in Research Square
Linc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation
Background: Cholangiocarcinoma (CCA) is a mortal cancer with high mortality, whereas the function and mechanism of occurrence and progression of CCA are still mysterious. Long non-coding RNAs (lncRNAs) could function as important regulators in carcinogenesis and cancer progression. Growing evidences have indicated that the novel lncRNA linc00473 plays an important role in cancer progression and metastasis. However, its function and molecular mechanism in CCA remain unknown. Methods: The linc00473 expression in CCA tissues and cell lines was analyzed using qRT-PCR. Gain- and loss-of-function experiments were conducted to investigate the biological functions of linc00473 both in vitro and in vivo. Insights into the underlying mechanisms of competitive endogenous RNAs (ceRNAs) were determined by bioinformatics analysis, dual-luciferase reporter assays, qRT-PCR arrays, RNA immunoprecipitation (RIP) and rescue experiments. Results: Linc00473 was highly expressed in CCA tissues and cell lines. Linc00473 knockdown inhibited CCA growth and metastasis. Furthermore, linc00473 acted as miR-506 sponge and regulated its target gene DDX5 expression. Rescue assays verified that linc00473 modulated the tumorigenesis of CCA by regulating miR-506. Conclusions: The data indicated that linc00473 played an oncogenic role in CCA growth and metastasis, and could serve as a novel molecular target for treating CCA.
- 24 June 2020
- Published by Springer Nature in Research Square
Open AccessLinc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation
Background: Cholangiocarcinoma (CCA) is a mortal cancer with high mortality, whereas the function and mechanism of occurrence and progression of CCA are still mysterious. Long non-coding RNAs (lncRNAs) could function as important regulators in carcinogenesis and cancer progression. Growing evidences have indicated that the novel lncRNA linc00473 plays an important role in cancer progression and metastasis. However, its function and molecular mechanism in CCA remain unknown. Methods: The linc00473 expression in CCA tissues and cell lines was analyzed using qRT-PCR. Gain- and loss-of-function experiments were conducted to investigate the biological functions of linc00473 both in vitro and in vivo. Insights into the underlying mechanisms of competitive endogenous RNAs (ceRNAs) were determined by bioinformatics analysis, dual-luciferase reporter assays, qRT-PCR arrays, RNA immunoprecipitation (RIP) and rescue experiments. Results: Linc00473 was highly expressed in CCA tissues and cell lines. Linc00473 knockdown inhibited CCA growth and metastasis. Furthermore, linc00473 acted as miR-506 sponge and regulated its target gene DDX5 expression. Rescue assays verified that linc00473 modulated the tumorigenesis of CCA by regulating miR-506. Conclusions: The data indicated that linc00473 played an oncogenic role in CCA growth and metastasis, and could serve as a novel molecular target for treating CCA.
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 7739-7749
Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma
Introduction: Growing evidence suggests that long non-coding RNAs (lncRNAs) could function as important regulators in carcinogenesis and cancer progression. Nicotinamide nucleotide transhydrogenase antisense RNA 1 (lncRNA NNT-AS1) is up-regulated in some human tumors and functions as a tumor promoter. This study aimed to detect the effect of NNT-AS1 on cholangiocarcinoma (CCA) prognosis. Materials and methods: In this study, we detected NNT-AS1 expression in CCA tissue samples and cell lines, and analyzed the association between NNT-AS1 expression levels and clinical parameters of CCA patients. Moreover, we conducted loss-of-function studies in CCA cancer cells to explore the biological function and molecular mechanism of NNT-AS1. NNT-AS1 was downregulated by using RNAi technology. Cell proliferation was examined by CCK8 and clone formation assays. Cell migration and invasion were determined by wound healing and transwell assays. Western blot assays were used to explore protein expression. Results: In this study, NNT-AS1 was expressed at high levels in CCA and closely associated with poor prognosis of patients with CCA. NNT-AS1 knockdown impaired cell proliferation, suppressed CCA cell migration and invasion, and restrained tumor growth in vitro. Moreover, NNT-AS1 directly bounded to miR-485 and further regulated BCL9. Finally, rescue assays verified that NNT-AS1 modulated the tumorigenesis of CCA by regulating miR-485. Conclusion: Taken together, NNT-AS1 played a critical biological role in the development of CCA. Our results elucidated NNT-AS1/miR-485/BCL9 axis might lead to a further understanding of the molecular mechanism of CCA.
- 1 August 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 7739-7749
Open AccessLong non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma
Introduction: Growing evidence suggests that long non-coding RNAs (lncRNAs) could function as important regulators in carcinogenesis and cancer progression. Nicotinamide nucleotide transhydrogenase antisense RNA 1 (lncRNA NNT-AS1) is up-regulated in some human tumors and functions as a tumor promoter. This study aimed to detect the effect of NNT-AS1 on cholangiocarcinoma (CCA) prognosis. Materials and methods: In this study, we detected NNT-AS1 expression in CCA tissue samples and cell lines, and analyzed the association between NNT-AS1 expression levels and clinical parameters of CCA patients. Moreover, we conducted loss-of-function studies in CCA cancer cells to explore the biological function and molecular mechanism of NNT-AS1. NNT-AS1 was downregulated by using RNAi technology. Cell proliferation was examined by CCK8 and clone formation assays. Cell migration and invasion were determined by wound healing and transwell assays. Western blot assays were used to explore protein expression. Results: In this study, NNT-AS1 was expressed at high levels in CCA and closely associated with poor prognosis of patients with CCA. NNT-AS1 knockdown impaired cell proliferation, suppressed CCA cell migration and invasion, and restrained tumor growth in vitro. Moreover, NNT-AS1 directly bounded to miR-485 and further regulated BCL9. Finally, rescue assays verified that NNT-AS1 modulated the tumorigenesis of CCA by regulating miR-485. Conclusion: Taken together, NNT-AS1 played a critical biological role in the development of CCA. Our results elucidated NNT-AS1/miR-485/BCL9 axis might lead to a further understanding of the molecular mechanism of CCA.